HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strauss, L. G. Articles by Thiesen, H.-J. Search for Related Content PubMed PubMed Citation Articles by Strauss, L. G. Articles by Thiesen, H.-J.

¹⁸F-FDG Kinetics and Gene Expression in Giant Cell Tumors

¹ Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
² Institute of Immunology, University Rostock, Rostock, Germany
³ Department I, University Orthopedic Clinic, Heidelberg, Germany

¹⁸F-FDG kinetics were evaluated by use of compartment and noncompartment models of giant cell tumors. The kinetic data were compared with the gene expression data for a subgroup of patients. Methods: Nineteen patients with giant cell tumors were examined with PET and ¹⁸F-FDG, and tracer kinetics were assessed quantitatively. A 2-compartment model, including the transport constants k1–k4 as well as the vascular fraction (VB) for ¹⁸F-FDG, was used for evaluation of the data. A noncompartment model was used to calculate the fractal dimension of the ¹⁸F-FDG time–activity curve to assess the heterogeneity of the tracer kinetics. Furthermore, tumor specimens obtained from 5 patients were assessed with gene chip technology (U95A), and these data were compared with the quantitative ¹⁸F-FDG data. Results: The giant cell tumors showed generally enhanced ¹⁸F-FDG uptake 1 h after tracer application, with a mean ¹⁸F-FDG standardized uptake value (SUV) of 4.8 (range, 1.8–9.4). Quantitative evaluation of tracer kinetics showed a preferential increase for ¹⁸F-FDG transport, with a mean k1 of 0.340. The vascular fraction accounted for 35% of the tumor volume and was high compared with those for other tumors, such as soft-tissue sarcomas. ¹⁸F-FDG kinetics were heterogeneous, with a fractal dimension of 1.3. Gene chip analysis showed that the expression of 137 genes (1.1%) exceeded the median expression value of the reference gene, ß₂-microglobulin. The highest expression was observed for the gene for the small, leucine-rich proteoglycan I (biglycan), which is important for bone cell differentiation and proliferative activity. Correlation analysis revealed an association of ¹⁸F-FDG data with the expression of several genes. Mainly genes related to angiogenesis were associated with the compartment parameters. The SUV at 56–60 min was correlated with the expression of vascular endothelial growth factor A (angiogenesis) and cell division cycle 2 protein (proliferation). Conclusion: Despite their classification as benign tumors, giant cell tumors have generally enhanced ¹⁸F-FDG uptake, mainly attributable to an enhanced vascular fraction and increased ¹⁸F-FDG transport. A comparison of gene chip data and ¹⁸F-FDG kinetic data showed a close association of quantitative ¹⁸F-FDG results and the expression of genes related to angiogenesis.

Key Words: giant cell tumor • ¹⁸F-FDG • quantification • gene expression

Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8A-9A. [Full Text]  

This article has been cited by other articles:

				L. G. Strauss, D. Koczan, S. Klippel, L. Pan, C. Cheng, S. Willis, U. Haberkorn, and A. Dimitrakopoulou-Strauss Impact of Angiogenesis-Related Gene Expression on the Tracer Kinetics of 18F-FDG in Colorectal Tumors J. Nucl. Med., August 1, 2008; 49(8): 1238 - 1244. [Abstract] [Full Text] [PDF]

				A. J. Beer, S. Lorenzen, S. Metz, K. Herrmann, P. Watzlowik, H.-J. Wester, C. Peschel, F. Lordick, and M. Schwaiger Comparison of Integrin {alpha}v 3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG J. Nucl. Med., January 1, 2008; 49(1): 22 - 29. [Abstract] [Full Text] [PDF]

				A. Dimitrakopoulou-Strauss, P. Hohenberger, U. Haberkorn, H. R. Macke, M. Eisenhut, and L. G. Strauss 68Ga-Labeled Bombesin Studies in Patients with Gastrointestinal Stromal Tumors: Comparison with 18F-FDG J. Nucl. Med., August 1, 2007; 48(8): 1245 - 1250. [Abstract] [Full Text] [PDF]

				T. Maeda, U. Tateishi, T. Terauchi, C. Hamashima, N. Moriyama, Y. Arai, E. E. Kim, and K. Sugimura Unsuspected Bone and Soft Tissue Lesions Identified at Cancer Screening using Positron Emission Tomography Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 207 - 215. [Abstract] [Full Text] [PDF]

				A.M. McKinney, P. Reichert, J. Short, T. Dhurairaj, K. SantaCruz, Z. McKinney, and S. Kieffer Metachronous, Multicentric Giant Cell Tumor of the Sphenoid Bone with Histologic, CT, MR Imaging, and Positron-Emission Tomography/CT Correlation AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2199 - 2201. [Abstract] [Full Text] [PDF]